| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 1/6 |
Shanghai Rightongene Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.81 |
| 52 Week High | CN¥43.79 |
| 52 Week Low | CN¥19.34 |
| Beta | 0.082 |
| 1 Month Change | -9.91% |
| 3 Month Change | -11.46% |
| 1 Year Change | -42.54% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.69% |
Recent News & Updates
Shareholder Returns
| 688217 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 8.6% | 2.5% | 2.2% |
| 1Y | -42.5% | -24.0% | -14.2% |
Return vs Industry: 688217 underperformed the CN Biotechs industry which returned -24% over the past year.
Return vs Market: 688217 underperformed the CN Market which returned -14.2% over the past year.
Price Volatility
| 688217 volatility | |
|---|---|
| 688217 Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 8.0% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 688217 has not had significant price volatility in the past 3 months.
Volatility Over Time: 688217's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 501 | Hui Xiong | www.rightongene.com |
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. It also provides molecular diagnostic reagents, and scientific research and testing services for blood diseases, solid tumors, and infectious diseases. The company was founded in 2012 and is based in Shanghai, China.
Shanghai Rightongene Biotechnology Co., Ltd. Fundamentals Summary
| 688217 fundamental statistics | |
|---|---|
| Market cap | CN¥1.39b |
| Earnings (TTM) | CN¥7.17m |
| Revenue (TTM) | CN¥265.52m |
193.2x
P/E Ratio5.2x
P/S RatioIs 688217 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688217 income statement (TTM) | |
|---|---|
| Revenue | CN¥265.52m |
| Cost of Revenue | CN¥65.42m |
| Gross Profit | CN¥200.10m |
| Other Expenses | CN¥192.93m |
| Earnings | CN¥7.17m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 75.36% |
| Net Profit Margin | 2.70% |
| Debt/Equity Ratio | 2.3% |
How did 688217 perform over the long term?
See historical performance and comparison